Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue	$ 9,831,814	$ 3,754,389
Cost of revenue	3,222,184	1,455,345
Gross profit	6,609,630	2,299,044
Operating expenses:
Research and development	1,790,024	956,215
Selling, clinical and marketing	4,395,804	2,361,845
General and administrative	3,944,056	2,869,751
Total operating expenses	10,129,884	6,187,811
Loss from operations	(3,520,254)	(3,888,767)
Other (income) expense, net
Interest income, net	(191,991)	(135,293)
Total other expense (income), net	(191,991)	(135,293)
Loss before income taxes	(3,328,263)	(3,753,474)
Income tax expense	136,795	82,158
Net loss	$ (3,465,058)	$ (3,835,632)
Weighted average number of common shares outstanding:
Basic	41,454,472	36,752,597
Diluted	41,454,472	36,752,597
Net loss per share attributable to common stockholders
Basic	$ (0.08)	$ (0.1)
Diluted	$ (0.08)	$ (0.1)
Product revenue
Revenue	$ 9,831,814	$ 3,754,389